Sangamo Therapeutics (NASDAQ:SGMO) Earns Sell Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. SGMO has been the topic of several other research reports. Royal Bank of Canada reaffirmed a sector perform rating and set a $2.00 […]
More Stories
General Mills Announces Removal of Synthetic Food Dyes, Starting With Cereals
By Naveen Athrappully General Mills, which owns a wide range of snack and baked products in the United States, announced...
Federal Reserve Keeps Interest Rates Unchanged, Signals 2 Cuts This year
By Andrew Moran The Federal Reserve kept interest rates unchanged for the fourth straight meeting on June 18, a decision...
Trust Point Inc. Cuts Position in The Boeing Company (NYSE:BA)
Trust Point Inc. decreased its position in The Boeing Company (NYSE:BA – Free Report) by 15.4% during the first quarter,...
Prime Day Just Got Even Better With Amazon’s Exciting Free Game Offers
Ahead of the long-awaited Prime Day 2025, Amazon has already started offering a surprise to its Prime Members – free...
Exchange Traded Concepts LLC Reduces Position in Merck & Co., Inc. (NYSE:MRK)
Exchange Traded Concepts LLC decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 74.8%...
Capital One Shopping Review: Save More While You Shop Online
In this digital shopping era, getting your hands on the best deals can be a little time-consuming, but not for...